Clinical Trial Update: Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations. [Phase 2]

View source ↗

Summary

Phase II trial of amivantamab plus single-agent chemotherapy in platinum-unfit NSCLC with EGFR exon 20 insertion is currently recruiting. Sponsored by Fondazion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Rybrevant (amivantamab) (amivantamab)

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING